Section Arrow
GYRE.NASDAQ
- Gyre Therapeutics
Quotes are at least 15-min delayed:2026/04/10 21:25 EDT
Regular Hours
Last
 7.39
+0.15 (+2.07%)
Day High 
7.41 
Prev. Close
7.24 
1-M High
8.51 
Volume 
47.01K 
Bid
5.56
Ask
7.9
Day Low
7.19 
Open
7.26 
1-M Low
6.58 
Market Cap 
661.11M 
Currency 美元 
P/E 362 
%Yield 46.94 
10-SMA 7.06 
20-SMA 7.14 
50-SMA 7.72 
52-W High 11.78 
52-W Low 6.57 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.02/-0.17
Enterprise Value
661.42M
Balance Sheet
Book Value Per Share
1.16
Cash Flow
Cash Flow Yield
0.00
Income Statement
Total Revenue
116.59M
Operating Revenue Per Share
1.11
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CUECue Biopharma0.5019+0.209+71.36%-- 
QNCXQuince Therapeutics0.1363+0.0126+10.19%-- 
VRAXVirax Biolabs Group Limited0.1041-0.0308-22.83%-- 
ZNTLZentalis Pharmaceuticals6.61+2.19+49.55%-- 
IOVAIovance Biotherapeutics3.7-0.31-7.73%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liverfibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.